BostonGene Named ‘Innovator of the Year’ at Boston Life Sciences Times Vanguard Awards

AI Foundation Models Accelerate Oncology Drug Development Pipeline and Optimize Probability of Technical Success

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and the immune biology, today announced it has been honored as the Innovator of the Year at the 2025 Life Sciences Times Vanguard Awards. This award recognizes the company's integrated cancer and immune system foundation models, purpose-built to accelerate oncology drug development.

This recognition validates BostonGene’s success in addressing the industry’s critical challenge: the profound inefficiency and high failure rate in oncology drug development. BostonGene’s platform moves beyond fragmented, traditional approaches to provide a complete biological picture of cancer.

“We are incredibly honored to be named Innovator of the Year by the Life Sciences Times Vanguard Awards,” said Andrew Feinberg, President and CEO of BostonGene. “This award validates our conviction that achieving depth—a mechanistic understanding of both the tumor and the immune system—is the only way to effectively de-risk the oncology pipeline. Our AI platform provides the decision-ready evidence needed to increase probability of success, shorten development cycles, and confidently bring life-changing therapies to patients faster.”

The award-winning innovation centers on BostonGene’s omnimodal foundation models, which fuse genomics, transcriptomics, spatial biology, and proteomics into a unified architecture. This powers the BostonGene Digital Twin, enabling sponsors to simulate treatment response and predict therapeutic efficacy with unprecedented accuracy. By leveraging this technology, pharmaceutical R&D teams can perform in silico hypothesis testing with biological realism, refine trial design through data-driven patient stratification, and realize a measurable increase in PTS across the entire drug development lifecycle. These capabilities are already being utilized by partners to make earlier, more confident go/no-go decisions, driving measurable improvements in development efficiency and PTS across complex oncology programs.

As the industry shifts toward predictive modeling, BostonGene is positioned to become the core decision engine for oncology R&D worldwide, setting a new standard for how life-changing therapies are brought to market.

About BostonGene Corporation
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.